Acrivon Therapeutics
ACRV
43 hedge funds and large institutions have $144M invested in Acrivon Therapeutics in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 15 increasing their positions, 12 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
25% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 12
8% more funds holding
Funds holding: 40 → 43 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.59% less ownership
Funds ownership: 68.98% → 68.39% (-0.59%)
21% less capital inflows, than outflows
Capital inflows: $1.45M | Capital outflows: $1.83M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$753K |
| 2 |
JP Morgan Chase
New York
|
+$227K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$128K |
| 4 |
State Street
Boston,
Massachusetts
|
+$84.3K |
| 5 |
Charles Schwab
San Francisco,
California
|
+$77.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$902K |
| 2 |
NEA Management Company
Timonium,
Maryland
|
-$594K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$112K |
| 4 |
BlackRock
New York
|
-$53.1K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$52.6K |
ACRV Hedge Fund Activity: Q3 2023 in Review
43 of the 6,316 institutional investors tracked by Wall St. Rank reported a position in Acrivon Therapeutics (ACRV) for Q3 2023, worth a combined $144M — down 26% from $196M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new ACRV positions and 1 closed out — a net gain of 3 holders — while 15 added to existing stakes and 12 trimmed.
The largest buyer was Vanguard Group, adding an estimated $753K. The largest seller was Federated Hermes, cutting an estimated $902K.
- 43 institutional investors held Acrivon Therapeutics (ACRV) as of Q3 2023, up from 40 in Q2 2023.
- Funds reported $144M of Acrivon Therapeutics stock for Q3 2023, down 26% quarter-over-quarter.
- 4 funds opened new Acrivon Therapeutics positions in Q3 2023 and 1 closed out, a net change of +3 holders.
- The largest Acrivon Therapeutics buyer in Q3 2023 was Vanguard Group, an estimated $753K added.
- The largest Acrivon Therapeutics seller in Q3 2023 was Federated Hermes, an estimated $902K sold.
Based on aggregated 13F filings for Q3 2023.